Chondroitin Sulphate and Glucosamine Use Depend on Nonsteroidal Anti-inflammatory Drug Use to Modify the Risk for Colorectal Cancer

  title={Chondroitin Sulphate and Glucosamine Use Depend on Nonsteroidal Anti-inflammatory Drug Use to Modify the Risk for Colorectal Cancer},
  author={Gemma Ib{\'a}{\~n}ez‐Sanz and Elisabet Guin{\'o} and Rosa Morros and Mª {\'A}ngeles Quijada-Manuitt and Luisa Carmen de la Pe{\~n}a-Negro and V{\'i}ctor Moreno},
  journal={Cancer Epidemiology, Biomarkers \& Prevention},
  pages={1809 - 1816}
Background: A safe and effective colorectal cancer chemoprevention agent remains to be discovered. There is little evidence regarding the protective effect of chondroitin sulphate and glucosamine on colorectal cancer. We aimed to assess the association between colorectal cancer risk and the use of chondroitin sulphate and glucosamine using a large cohort with dispensed data. Methods: We performed a population-based case–control study in Catalonia using primary care reimbursed medication records… Expand


Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study
The MCC-Spain study has not found strong evidence of an independent preventive effect of CG on CRC in the population because the observed effects could be attributed to NSAIDs concurrent use, and these results merit further research due to the safety profile of these drugs. Expand
Use of glucosamine and chondroitin supplements and risk of colorectal cancer
There is great need to identify safe and effective cancer preventive strategies, suggesting that glucosamine and chondroitin may merit further attention as a potential chemopreventive agent. Expand
Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow‐up study
A protective association between use of glucosamine and chondroitin and risk of CRC is supported and further study is needed to better understand the chemopreventive potential of these supplements. Expand
Randomized Trial of Glucosamine and Chondroitin Supplementation on Inflammation and Oxidative Stress Biomarkers and Plasma Proteomics Profiles in Healthy Humans
A randomized, double-blind, placebo-controlled, cross-over study to assess the effects of glucosamine hydrochloride plus chondroitin sulfate for 28 days compared to placebo in healthy, overweight adults, adding evidence for potential mechanisms supporting epidemiologic findings that glucosamines and chond Detroitin are associated with reduced risk of lung and colorectal cancer. Expand
Risk of colorectal cancer in users of bisphosphonates: analysis of population-based electronic health records
The use of bisphosphonates was associated with a modest decrease in the risk of CRC, but this effect was essentially explained by concomitant use of calcium or vitamin D. Expand
Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort
Current use of glucosamine, modeled using a time-varying exposure, was associated with lower risk of CRC compared to never use, but for reasons that are unclear, this reduction in risk was observed for shorter-duration use rather than longer- duration use. Expand
Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation.
The results support prior research suggesting that use of glucosamine and chondroitin is associated with reduced hsCRP and PGE2, but further work is needed to more definitively evaluate the anti-inflammatory potential of these supplements. Expand
Statin use and the risk of colorectal cancer in a population-based electronic health records study
This study does not support an overall protective effect of statins in CRC, but a protective association with rectal cancer merits further research. Expand
Risk assessment for glucosamine and chondroitin sulfate.
The OSL risk assessment method indicates that the evidence strongly supports safety at intakes up to 2000 mg/d for glucosamine, and 1200 mg/D for chondroitin sulfate, and these levels are identified as the respective OSL. Expand
Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.
Generic approaches to improve the balance between benefits and risks associated with the use of NSAIDs in chemoprevention are considered and strategies to overcome the various logistic and scientific barriers that impede clinical trials ofNSAIDs for cancer prevention are identified. Expand